Pathologic Lymph Node Staging Practice and Stage- Predicted Survival After Resection of Lung Cancer
|
|
- Colleen Franklin
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at To take the CME activity related to this article, you must have either an STS member or an individual non-member subscription to the journal. Pathologic Lymph Node Staging Practice and Stage- Predicted Survival After Resection of Lung Cancer Raymond U. Osarogiagbon, MD, Jeffrey W. Allen, MD, Aamer Farooq, MD, Allen Berry, MD, and Thomas O Brien, MD Division of Hematology/Medical Oncology, University of Tennessee Health Sciences Center, Memphis; Division of Oncology, Roswell Park Cancer Institute, Buffalo, New York; Department of Pathology, St. Francis Hospital, Memphis; and Duckworth Pathology Group, Memphis, Tennessee Background. Lymph node status is the most important prognostic factor in resectable nonsmall-cell lung cancer (NSCLC). We examined the relationship between the pattern of lymph node examination (including the number and anatomic location of resected lymph nodes), pathologic nodal stage, and survival after NSCLC resection. Methods. Retrospective review of all NSCLC resections in the Memphis Metropolitan Area from January 1, 2004, to December 31, Results. In 656 resections, the number of lymph nodes examined differed significantly between patients grouped by pathologic nodal stage (p < ) and extent of resection (p < 0.001). Thirty-seven percent of mediastinal nodenegative patients had no mediastinal lymph nodes examined. Patients with pn1 and no mediastinal lymph nodes had significantly worse survival than patients with mediastinal lymph node examination (p < 0.02). Approximately 10% of patients with pn0 and pn2 disease had no hilar/ intrapulmonary lymph nodes examined. Conclusions. Suboptimal lymph node staging was prevalent in this cohort. Large proportions of pn1 and pn0 patients were probably understaged. For patients with positive pulmonary/hilar lymph nodes, failure to examine mediastinal lymph nodes was associated with poorer survival. Interventions are needed to improve lymph node staging of NSCLC. (Ann Thorac Surg 2011;91: ) 2011 by The Society of Thoracic Surgeons Only about 28% of all patients with nonsmall-cell lung cancer (NSCLC) are candidates for surgical resection because most present with advanced disease or significant comorbidity that preclude surgery [1]. This minority group eligible for surgery forms the vast majority of long-term survivors. For them, the status of lymph node involvement is the key determinant of prognosis. The location (peripheral/hilar versus mediastinal) and number of lymph nodes with metastasis are related but independent prognostic factors [2, 3]. The median survival of patients with pathologic (p) N0, N1, N2, and N3 disease is 77, 34, 21, and 12 months, respectively [4]. Postoperative adjuvant chemotherapy improves the survival of patients with lymph node metastasis [5 7]; patients with mediastinal lymph node metastasis may also benefit from radiation therapy [8, 9]. Therefore, it is incumbent on surgeons to obtain sufficient lymph nodes from both clusters of stations to enable accurate evaluation of nodal stage [10], and on pathologists to retrieve and examine all lymph nodes in the submitted resection specimen [11]. Heterogeneity in surgical [12] and pathology [13] practice Accepted for publication Nov 29, Address correspondence to Dr Osarogiagbon, University of Tennessee Cancer Institute, 1331 Union Ave, Ste 800, Memphis, TN 38104; rosarogi@uthsc.edu. impairs stage-based prognostication. For example, patients in whom no lymph nodes are examined (pnx) have a significantly worse survival than patients with pn0 who have at least one lymph node examined [14]; and pn0 patients with fewer than 10 lymph nodes examined have worse survival than patients with more than 10 examined lymph nodes [15]. These findings probably reflect differences in the accuracy of staging. We hypothesized that the likelihood of finding lymph node metastasis (and higher pn stage) is directly related to the number and location of lymph nodes examined. We expected that more thorough harvesting of lymph nodes would lead to more accurate reflection of true pathologic stage. We studied the relationship between pathologic nodal stage and the number of lymph nodes examined to determine if patients with more lymph nodes examined were more likely to have node-positive disease. We also investigated the factors associated with increased lymph node examination and compared the survival of patients with and without mediastinal lymph node examination. Patients and Methods We conducted a retrospective review of the Memphis Metropolitan Area Quality of Surgical Resection (MMA by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg OSAROGIAGBON ET AL 2011;91: LYMPH NODE STAGING PRACTICE AND SURVIVAL 1487 QSR) cohort, a community-wide database from all hospitals where lung cancer surgery was routinely performed in the greater Memphis Metropolitan Area from January 1, 2004, to December 31, The dataset includes details about patients, their surgeons, lung resection procedures, and pathology examination. The Institutional Review Boards of the University of Tennessee and all participating hospitals approved this study and waived the informed consent requirement. For this analysis, we excluded patients who received preoperative chemotherapy or radiation therapy. We also excluded those who had no lymph nodes examined, because we have previously reported their inferior survival statistics [14]. Patients with incomplete resections and patients with metastatic disease were excluded from analyses of survival. We compared the demographic and clinical characteristics of patients with the different pn stages. We also compared the survival of patients in the pn subgroups according to the number and location of examined lymph nodes. All references to TNM staging are to the sixth edition of the American Joint Commission on Cancer system, which was in use during the time span of this study. Statistical Analysis Categorical variables were compared by the 2 test, or Fishers exact test when the expected cell frequencies were low. Differences in medians were tested by the Wilcoxon- Mann-Whitney test when there were two groups, or the Kruskal-Wallis test when there were more than two groups. Survival was estimated by the Kaplan-Meier method, and survival curves were compared by the log rank test. All tests of statistical significance were two-sided. The level of significance was set at 0.05, with no adjustments for multiple testing. Results MMA-QSR Cohort A total of 806 patients had a curative-intent resection for primary lung cancer. We excluded 60 patients who had preoperative chemotherapy or radiation therapy, or both, and 90 with no lymph nodes examined from further analysis, leaving a final cohort of 656 patients. Ninety-five percent of the resections were performed by board-certified cardiothoracic surgeons. No resections were performed by general surgeons. All institutions contributing to the MMA- QSR dataset were in urban or suburban locations. Patient and Disease Characteristics The majority of patients (77%) had pn0 disease; none had pn3 disease (Table 1). Patient characteristics were similar across the pn stage groups. Adenocarcinoma was more frequent than other histologic types in the pn2 subset (p 0.003). Although the T-stage distribution was similar among patients in the three N-stage subgroups, the pneumonectomy rate was significantly higher in patients with nodepositive disease (pn1 and pn2), as was the rate of resection with positive margins (Table 2). Extent of Resection and Lymph Node Examination The number of lymph nodes examined was significantly associated with the extent of resection (Table 3). Patients undergoing pneumonectomy had a higher median number of lymph nodes examined (9) compared with patients undergoing lobectomy/bilobectomy (5) and patients with sublobar resection (3; p ). This pattern was consistent within each pathologic nodal stage (Table 3). The likelihood of finding lymph node metastasis was greatest in patients who underwent a pneumonectomy (51%) compared with lobectomy/bilobectomy (19%) or sublobar resection (22%; p for comparison be- Table 1. Demographic and Disease Characteristics Characteristic pn0 Disease n 506 (77%) pn1 Disease n 94 (14%) pn2 Disease n 56 (9%) Age, years, median (range) 68 (42 89) 66 (27 84) 65 (39 85) 0.15 Sex, n (%) 0.52 Female 240 (47) 40 (43) 29 (51) Male 266 (53) 54 (58) 27 (48) Race 0.11 Black 106 (20) 25 (27) 18 (32) White 397 (79) 67 (71) 38 (68) Histology Adenocarcinoma 218 (43) 37 (39) 39 (66) Squamous 192 (37.9) 39 (42) 7 (13) Other 96 (19) 18 (19) 12 (21) T stage (49) 38 (40) 23 (41) (38) 43 (46) 24 (43) 3 18 (4) 5 (5) 4 (7) 4 40 (8) 8 (9) 5 (9)
3 1488 OSAROGIAGBON ET AL Ann Thorac Surg LYMPH NODE STAGING PRACTICE AND SURVIVAL 2011;91: Table 2. Comparison of Surgical and Lymph Node Examination Details pn0 Disease n 506 (77%) pn1 Disease n 94 (14%) pn2 Disease n 56 (9%) Extent of resection Pneumonectomy 40 (8) 27 (29) 14 (25) Lobe/bilobectomy 438 (87) 66 (70) 35 (63) Segmental/wedge 28 (6) 1 (1) 7 (13) Resection margins R0 474 (95) 83 (91) 43 (80) R1/R2 23 (5) 8 (9) 11 (20) Number of lymph nodes examined, median (range) All stations 5 (1 45) 6 (1 28) 7 (1 35) Hilar/intrapulmonary, stations 10 to 14 3 (0 38) 4 (1 22) 3 (0 24) Mediastinal, stations 1 to 9 1 (0 29) 1 (0 10) 3 (1 12) Percentage with 10 lymph nodes Number with no lymph nodes from 10 to 14, n (%) 46 (9) 0 (0) 6 (11) Number with no lymph nodes from 1 to 9, n (%) 179 (35) 45 (48) 0 (0) tween pneumonectomy and both types of lesser resection). Number, Location of Examined Lymph Nodes, and pn Stage The median number of lymph nodes examined in the whole cohort was 5 (range, 1 to 45). It generally increased with increasing pn stage (Table 2). Although patients with pn0 and pn1 had similar total number of lymph nodes (p 0.07), the location differed. Patients with pn1 had significantly more nodes examined from the hilar/ intrapulmonary stations than patients with pn0 (p ), whereas patients with pn0 had slightly more mediastinal lymph nodes examined (p 0.03). Patients with pn1 and pn2 disease had slight differences in the numbers of total and hilar/intrapulmonary lymph nodes examined (p 0.14 and 0.29, respectively), but those with pn2 had significantly more mediastinal lymph nodes examined (p ). There were significantly more total and mediastinal lymph nodes examined in patients with pn2 than in patients with pn0 (p and , respectively), whereas there was no difference in the number of hilar/intrapulmonary lymph nodes examined (p 0.2). The median number of mediastinal lymph nodes examined in the whole cohort was 1 (range, 0 to 29). Thirty-seven percent of the 600 patients without mediastinal lymph node metastasis had no mediastinal lymph nodes examined (35% of pn0 and 48% of pn1 patients). Conversely, 9% of patients with pn0 and 11% with pn2 had no N1 lymph nodes examined. Nineteen of the 50 pn2 patients (38%) with both N1 and N2 lymph nodes examined had negative N1 lymph nodes (mediastinal skip metastasis). Number of Lymph Nodes and Likelihood of Lymph Node Positivity The proportion of patients with more than 10 lymph nodes examined increased significantly with advancing pn stage (p 0.02; Table 2). Twenty-one percent of patients with 10 or fewer lymph nodes had node positive disease, whereas 32% with more than 10 lymph nodes had lymph node metastasis. The likelihood that lymph nodes from both N1 and N2 stations were examined increased significantly with the number of lymph nodes examined, ranging from 37% in the 1 to 5 lymph node group, to 97% in the more than 15 lymph node group (p ; Table 4). The proportion of patients with lymph node metastasis also increased in direct association with the number of lymph nodes examined. Whereas 19% of the lowest cohort had any detected lymph node metastasis, 39% of the highest cohort did (p 0.035). Characteristics of Patients With High and Low Lymph Node Counts Patient characteristics were similar across the lymph node examination cohorts with the exception of median tumor size, which increased with increasing number of lymph nodes (p ). However, the incremental change in Table 3. Extent of Resection, Number of Examined Lymph Nodes, and Pathologic Nodal Stage Number of Lymph Nodes Examined Median (Range) Type of Resection N (%) All pn0 pn1 pn2 Pneumonectomy 81 (12) 9 (1 45) 7.5 (1 45) 8 (3 28) 10.5 (2 35) 0.52 Bilobectomy/lobectomy 539 (82) 5 (1 36) 5 (1 36) 5 (1 18) 7 (1 17) Segmentectomy/wedge 36 (5) 3 (1 13) 3 (1 13) 1 3 (1 5) 0.49
4 Ann Thorac Surg OSAROGIAGBON ET AL 2011;91: LYMPH NODE STAGING PRACTICE AND SURVIVAL 1489 Table 4. Comparison of Patients Sorted Into Categories According to Number of Lymph Nodes Examined, Whole Cohort Number of Lymph Nodes Examined, n (%) Variable 1 5 n 333 (51) 6 10 n 211 (32) n 74 (11) 15 n 38 (6) Age, median (range) 68 (42 86) 67 (37 89) 66 (42 86) 67 (50 83) 0.56 Sex 0.36 Female 163 (49) 100 (47) 33 (45) 13 (34) Male 170 (51) 111 (53) 41 (55) 25 (66) Race 0.16 African American 69 (21) 54 (26) 21 (28) 5 (13) Caucasian 262 (79) 154 (73) 53 (72) 33 (87) Other 2 (1) 3 (1) 0 0 Histology 0.11 Adeno 154 (46) 91 (43) 34 (46) 13 (34) Squamous 114 (34) 74 (35) 28 (38) 22 (58) Other 65 (20) 46 (22) 12 (16) 3 (8) Tumor size, median (range) 2.5 ( ) 2.7 ( ) 3.0 ( ) 3.5 ( ) T stage (55) 87 (41) 36 (49) 6 (16) (32) 99 (47) 31 (42) 26 (68) 3 14 (4) 8 (4) 3 (4) 2 (5) 4 29 (9) 16 (8) 4 (5) 4 (11) X 3 (1) 1 (0) 0 0 No N1 nodes 44 (13) 6 (3) 2 (3) No N2 nodes 165 (50) 49 (23) 9 (12) 1 (3) N1 and N2 present 124 (37) 156 (74) 63 (85) 37 (97) Percent with any positive nodes N stage (81) 161 (76) 53 (72) 23 (61) 1 43 (13) 31 (15) 11 (15) 9 (24) 2 21 (6) 19 (9) 10 (14) 6 (16) Extent of resection Bilobectomy/lobectomy 279 (84) 182 (86) 61 (82) 17 (45) Pneumonectomy 26 (8) 22 (10) 12 (16) 21 (55) Segmentectomy/wedge 28 (8) 7 (3) 1 (1) 0 median tumor size was small (Table 4), and despite this difference, the rates of pneumonectomy, lobectomy, or sublobar resection were similar, except for the cohort with more than 15 lymph nodes, in which the pneumonectomy rate was higher (55%, versus 8% for the 1 to 5 node group). When we restricted analysis to the lobectomy/bilobectomy population to eliminate the impact of extent of resection, we found no sequential difference in tumor size between patients in the various lymph node examination cohorts (Table 5). However, there continued to be significant differences in the likelihood of examination of lymph nodes from both N1 and N2 stations (p ) and a sequential, but statistically insignificant (p 0.32), increase in the identification of lymph node metastasis, ranging from 16% in the 1 to 5 lymph node group to 29% in the more than 15 node group. Survival Patients with pn0 had significantly better survival than patients with pn1 and pn2 disease (p ; Fig 1). However, there was no survival difference between patients with pn1 and pn2 (p 0.17). Patients with pn1 and no mediastinal lymph nodes examined had significantly worse survival than patients with at least one examined mediastinal node (p 0.02). These patients, with no mediastinal lymph nodes examined, had a survival curve that was very similar to that of patients with pn2 disease (Fig 2). This was dissimilar to the pn0 group, in which there was no difference between patients with or without mediastinal lymph nodes examined (Fig 3). Comment A large proportion of patients who underwent surgical resection for lung cancer in our community-based cohort did not have sufficient lymph nodes examined, irrespective of attributed pn stage. The median number of lymph nodes and the proportion of patients with more than 10 lymph nodes examined, a significant threshold for survival in patients with node-negative disease [15 18],
5 1490 OSAROGIAGBON ET AL Ann Thorac Surg LYMPH NODE STAGING PRACTICE AND SURVIVAL 2011;91: Table 5. Comparison of Patients Sorted Into Categories According to Number of Lymph Nodes Examined, Lobectomy/Bilobectomy Cohort Only Number of Lymph Nodes Examined, n (%) Variable 1 5 n n n n 17 Age 68 (42 85) 68 (39 89) 66 (42 86) 69 (50 83) 0.52 Sex 0.92 Female 138 (49) 86 (47) 28 (46) 9 (53) Male 141 (51) 96 (53) 33 (54) 8 (47) Race 0.30 African American 60 (22) 47 (26) 18 (30) 2 (12) Caucasian 217 (78) 133 (73) 43 (70) 15 (88) Other 2 (1) 2 (1) 0 (0) 0 (0) Tumor diameter 2.5 ( ) 2.5 ( ) 2.5 ( ) 3.4 ( ) T stage (55) 79 (43) 35 (57) 5 (29) 2 88 (32) 84 (46) 22 (36) 11 (65) 3 10 (4) 2 (1) 2 (3) 1 (6) 4 24 (9) 16 (9) 2 (3) 0 (0) X 3 (1) 1 (1) 0 (0) 0 (0) No N1 nodes 30 (11) 4 (2) 1 (2) 0 (0) No N2 nodes 152 (54) 42 (23) 8 (13) 1 (6) N1 and 2 nodes present 97 (32) 136 (75) 52 (85) 16 (94) N stage (84) 145 (80) 47 (77) 12 (71) 1 34 (12) 22 (12) 7 (11) 3 (18) 2 11 (4) 15 (8) 7 (11) 2 (12) were low in our cohort. The number of lymph nodes examined in each cluster of node stations was directly proportional to the pn stage. Patients with pn1 disease were more likely than patients with pn0 disease to have had hilar/intrapulmonary lymph nodes examined, and those with pn2 disease were more likely than those with pn0 or pn1 to have had mediastinal lymph nodes examined. This suggests an effect of sampling variation on the attribution of lymph node stage, raising questions about possible understaging of some patients with pn0 and pn1. Illustrative of the enormity of this risk is that 35% of pn0 and 48% of pn1 patients had no mediastinal lymph nodes examined. Although disappointing, the characteristics of the MMA-QSR cohort mirror national NSCLC surgical resection cohorts [14, 19]. Little and colleagues [12], in a Fig 1. Survival by pathologic N stage: N0 (blue line); N1 (red line); N2 (green line). p for comparison N0 versus N1 and N2. Fig 2. Survival of pathologic N1 patients with mediastinal (Med) lymph node examination (blue line) and without mediastinal lymph node examination (red line), compared with pathologic N2 patients (green line). p 0.02 for comparison N1 with mediastinal lymph node examination versus N1 without mediastinal lymph node examination.
6 Ann Thorac Surg OSAROGIAGBON ET AL 2011;91: LYMPH NODE STAGING PRACTICE AND SURVIVAL 1491 Fig 3. Survival of pathologic N0 patients with mediastinal (Med) lymph node examination (blue line) and without mediastinal lymph node examination (red line), compared with pathologic N2 patients (green line). p for comparison N0 with or without mediastinal lymph node examination versus N Patient Care Evaluation of the National Cancer Data Base, reported that 42% of NSCLC resections had no mediastinal lymph nodes examined. Ludwig and coworkers [15] reported that 42% of node-negative NSCLC resections with at least 1 examined lymph node in the 1990 to 2000 Surveillance, Epidemiology and End Results (SEER) cohort had only 1 to 4 total lymph nodes examined [15]. Varlotto and associates [18], reviewing SEER data from 1992 to 2002, showed that 49% of stage I NSCLC resections had no mediastinal lymph nodes examined, 83% had fewer than 10 total lymph nodes, and the median number of lymph nodes examined was between 4 and 6. We found an association between the extent of resection and likelihood of lymph node examination on the one hand, and extent of resection and advanced N stage, on the other hand. This cannot be satisfactorily explained by differences in T stage between patients who had more extensive resection and those with lesser resections, given the minimal differences in T-stage distribution between these patients (Table 1). Our finding that 20% and 25% of patients with T1 and T2 tumors, respectively, had positive lymph nodes suggests that T stage cannot be used to determine the need for systematic nodal evaluation. This point, previously made by others [20], is emphasized because of suggestions that patients with small peripheral tumors without hilar lymph node metastasis might not need mediastinal lymph node examination [21, 22]. The occurrence of skip metastases in 38% of the pn2 cohort indicates why avoiding mediastinal examination is risky. Theoretically, if the mediastinal nodes had not been examined, these patients would have been erroneously assumed to be pn0, with negative implications for subsequent therapy and outcomes. Although the similarity in survival between pn0 patients with and without examined mediastinal lymph nodes seems to support the idea that there is no need for mediastinal lymph node examination in patients with small peripheral T1 lesions in the absence of N1 lymph node involvement [21], the high skip metastasis rate coupled with the fact that 41% of the pn2 cohort had a T1 lesion argues against this idea. Interestingly, 9% of the pn0 group and 11% of the pn2 group had no lymph nodes examined from stations 10 to 14. The existence of this small group of patients suggests that pathologists bear some responsibility for suboptimal lymph node staging. Lymph nodes from peripheral stations are present in the resection specimen, irrespective of the surgeon s mediastinal lymph node harvest practice. This is probably one extreme end of a continuum of poor lymph node retrieval and examination practices in the pathology laboratory, which may have contributed to the low median number of N1 lymph nodes in the whole cohort (Table 2). Strategies to limit the extent of lymph node examination during lung cancer resection by either visual/ textural indicators [23, 24] or sentinel lymph node examination [25] fail to eliminate the need for systematic dissection of lymph nodes. Although it is not clear that radical mediastinal lymph node dissection is superior to systematic mediastinal lymph node sampling [22, 26 29], the studies that suggest equivalency between both types of surgical practice [22, 26] used a control arm with significantly more extensive mediastinal lymph node sampling than what we found in our cohort and what appears to be prevalent in routine US practice. Our study is limited by its retrospective design. Unexplained factors may account for the differences we have found in the number of lymph nodes between patients in the pn subgroups. For example, we cannot separate the effect of lymph node appearance and size on surgeon practice in collecting or not collecting certain lymph nodes, irrespective of their location; we may have missed information about preoperative mediastinoscopy that might have influenced surgeons intraoperative decisions; finally, we are unable to accurately distinguish between the relative weight of surgeon and pathologist practice. The practice of pathologic lymph node staging in this community-based cohort was poor, but reflective of overall US practice [12, 15, 18]. A large proportion of patients are exposed to the danger of underestimation of pn stage, with likely consequent failure to follow up with appropriate postoperative adjuvant therapy. Interventions are needed in the operating room and pathology laboratory to improve the examination of lymph nodes in patients who undergo lung cancer resection. One set of interventions must target intraoperative collection and mapping of lymph nodes, and another set of interventions must be directed at the retrieval and examination of lymph nodes from resection specimens in the pathology laboratory. Clinical trials of lung cancer resection and therapy after resection need to balance lymph node entry criteria to account for the heterogeneity of surgical and pathology practice, while avoiding the negative effect of excessively stringent entry criteria on patient accrual. We recommend stratification by quality of lymph node examination.
7 1492 OSAROGIAGBON ET AL Ann Thorac Surg LYMPH NODE STAGING PRACTICE AND SURVIVAL 2011;91: References 1. Little AG, Gay EG, Gaspar LE, Stewart AK, et al. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 2007;57: Fukui T, Mori S, Yokoi K, Mitsudomi T. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol 2006;1: Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected nonsmall-cell lung cancer predicts patient survival. Ann Thorac Surg 2008;85: Rusch VW, Crowley J, Giroux DJ, et al. The IASLC lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2: The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350: Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352: Pignon J, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26: PORT Meta-Analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 1998;352: Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24: Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005;49: Gal AA, Marchevsky AM, Travis WD. Updated protocol for the examination of specimens from patients with carcinoma of the lung. Arch Pathol Lab Med 2003;127: Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005;80: Gephardt GN, Baker PB. Lung carcinoma surgical pathology report adequacy: a College of American Pathologists Q- probes study of over 8300 cases from 464 institutions. Arch Pathol Lab Med 1996;120: Osarogiagbon RU, Allen JW, Farooq A, et al. Outcome of surgical resection for pathologic N0 and Nx non-small cell lung cancer. J Thorac Oncol 2010;5: Ludwig MS, Goodman M, Miller DL, Johnstone PAS. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest 2005;128: Gajra A, Newman N, Gamble GP, Kohman LJ, Granziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 2003;21: Ou SI, Zell JA. Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer. J Thorac Oncol 2008;3: Varlotto JM, Recht A, Nikolov M, Flickinger JC, DeCamp MM. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer 2009; 115: Allen JW, Farooq A, O Brien TF, Osarogiagbon RU. Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area. Cancer 2011;117: Graham ANJ, Chan KJM, Pastorino U, Goldstraw P. Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117: Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-smallcell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 1996; 111: Sugi K, Nawata K, Fukita N, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2cm in diameter. World J Surg 1998; 22: Arita T, Kuramitsu T, Kawamura M, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995;50: Prenzel KL, Monig SP, Sinning JM, et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest 2003;123: Liptay MJ, D Amico TA, Nwogu C, et al. Intraoperative sentinel node mapping with Technitium-99 in lung cancer: Results of CALGB multicenter phase II trial. J Thorac Oncol 2009;4: Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer. Ann Surg 1998;227: Keller SM, Adak S, Wagner H, Johnson DH. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa nonsmall-cell lung cancer. Ann Thorac Surg 2000;70: Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris H. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for nonsmall-cell lung cancer. Ann Thorac Surg 2005;80: Allen MS, Darlin GE, Pechet TTV, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006;81: INVITED COMMENTARY This retrospective review by Osarogiagbon and colleagues [1] of all non-small cell lung cancer resections, performed in the Memphis Metropolitan area during a 4-year time span, addresses an important issue affecting patients with resectable lung cancer. Adequacy of lymph node staging is crucial, because it provides the most important prognostic information in patients with locoregional non-small cell lung cancer. This is typically accomplished by a combination of imaging and surgical sampling. The extent of lymphadenectomy has been controversial, but at a minimum, systematic lymph node sampling is considered vital for adequate staging [2, 3]. Unfortunately, a large number of patients are inadequately staged [4]. This may negatively impact survival by depriving understaged patients of the potential benefits of adjuvant therapy. The National Comprehensive Cancer Network Guidelines (version ) for treatment of non-small cell lung cancer includes recommendations for the sampling of at least three N2 stations or complete 2011 by The Society of Thoracic Surgeons /$36.00 Published by Elsevier Inc doi: /j.athoracsur
Only about 16% of the approximately 200,000 persons
GENERAL THORACIC Nonexamination of Lymph Nodes and Survival After Resection of Non-Small Cell Lung Cancer Raymond U. Osarogiagbon, MBBS, and Xinhua Yu, MD, PhD Multidisciplinary Thoracic Oncology Program,
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationNumber of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer
Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel Fahey, BS, Sai Yendamuri, MD, Elisabeth Dexter, MD,
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationState of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter?
Review Article State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter? Laura Romero Vielva 1, Manuel Wong Jaen 1, José A. Maestre Alcácer 2, Mecedes Canela Cardona
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationNumber of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy
CHEST Original Research Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy Results of the Randomized, Prospective American College of Surgeons Oncology Group Z0030 Trial LUNG CANCER Gail
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationComparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Junhua Zhang*,
More informationVariability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival
Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B. Marks, MD, Richard H. Feins, MD, Benjamin
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationIn the mid 1970s, visceral pleural invasion (VPI) was included
ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationSelective lymph node dissection in early-stage non-small cell lung cancer
Review Article Selective lymph node dissection in early-stage non-small cell lung cancer Han Han 1,2, Haiquan Chen 1,2 1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationSublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer
Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationHistory of Limited Resection for Non-small Cell Lung Cancer
Review History of Limited Resection for n-small Cell Lung Cancer Haruhiko Nakamura, MD, PhD, 1 Sugishita Kazuyuki, MD, 1 rihito Kawasaki, MD, 1 Masahiko Taguchi, MD, PhD, 1 and Harubumi Kato, MD, PhD 2
More informationPostoperative Mortality in Lung Cancer Patients
Review Postoperative Mortality in Lung Cancer Patients Kanji Nagai, MD, Junji Yoshida, MD, and Mitsuyo Nishimura, MD Surgery for lung cancer frequently results in serious life-threatening complications,
More informationXing Wang *, Shi Yan *, Yaqi Wang, Xiang Li, Chao Lyu, Yuzhao Wang, Jia Wang, Shaolei Li, Lijian Zhang, Yue Yang, Nan Wu. Original Article.
Original Article Adjuvant chemotherapy may improve outcome of patients with non-small-cell lung cancer with metastasis of intrapulmonary lymph nodes after systematic dissection of N1 nodes Xing Wang *,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationLung cancer involving neighboring structures is classified
GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,
More informationA comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer
European Journal of Cardio-Thoracic Surgery 49 (2016) 580 588 doi:10.1093/ejcts/ezv134 Advance Access publication 18 April 2015 ORIGINAL ARTICLE Cite this article as: Lee GD, Kim DK, Moon DH, Joo S, Hwang
More informationEvaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationPredictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study
Moulla et al. Journal of Cardiothoracic Surgery (2019) 14:11 https://doi.org/10.1186/s13019-019-0831-0 RESEARCH ARTICLE Open Access Predictive risk factors for lymph node metastasis in patients with resected
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationKonrad Pawelczyk 1, Piotr Blasiak 1, Monika Szromek 1, Katarzyna Nowinska 2, Marek Marciniak 1. Original Article
Original Article Assessment of adequacy of intraoperative nodal staging and factors influencing the lack of its compliance with recommendations in the surgical treatment of non-small cell lung cancer (NSCLC)
More informationLung cancer is the leading cause of cancer deaths worldwide.
ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationSmall-cell lung cancer (SCLC) represents approximately
Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationMediastinal Lymph Node Dissection Improves Survival in Patients With Stages II and IIIa Non- Small Cell Lung Cancer
J. MAXWELL CHAMBERLAIN MEMORIAL PAPER Mediastinal Lymph Node Dissection Improves Survival in Patients With Stages II and IIIa Non- Small Cell Lung Cancer Steven M. Keller, MD, Sudeshna Adak, PhD, Henry
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationEver since Cahan 1 first introduced lymph node dissection
Original Article Mediastinal Nodal Involvement in Patients with Clinical Stage I Non Small-Cell Lung Cancer Possibility of Rational Lymph Node Dissection Tomohiro Haruki, MD,* Keiju Aokage, MD,* Tomohiro
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationThe Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene M. Correa, PhD, Ritsuko Komaki, MD, Joe Y. Chang,
More informationVATS lobectomy lymph node management
Perspective VATS lobectomy lymph node management Gavin M. Wright 1,2,3 1 Director of Surgical Oncology, St Vincent s Hospital, Melbourne, Australia; 2 Clinical Associate Professor, University of Melbourne
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationHiroyasu Ueno, Aritoshi Hattori, Takeshi Matsunaga, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki
Hiroyasu Ueno, Aritoshi Hattori, Takeshi Matsunaga, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki Is Lower Zone Mediastinal Nodal Dissection Always Mandatory for Lung Cancer in the Lower Lobe? Department of
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationAccepted Manuscript. Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD
Accepted Manuscript Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD PII: S0022-5223(18)31821-X DOI: 10.1016/j.jtcvs.2018.06.069 Reference: YMTC 13198 To appear in: The
More informationNode-Negative Non-small Cell Lung Cancer
ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationPulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationThe prognostic relevance of classifying neuroendocrine
Large Cell Neuroendocrine Carcinoma and Large Cell Carcinomas With Neuroendocrine Morphology of the Lung: Prognosis After Complete Resection and Systematic Nodal Dissection Joseph Zacharias, FRCS (CTh),
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationApplicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers
European Journal of Cardio-thoracic Surgery 36 (2009) 1031 1036 www.elsevier.com/locate/ejcts Applicability of the revised International Association for the Study of Lung Cancer staging system to operable
More informationRisk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
More informationPrognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer
Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,
More informationIn non small cell lung cancer, metastasis to lymph nodes, the N factor, is
Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,
More informationTreatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES Treatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Walter J.
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationSurvival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy
Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L. Chen, MD, MBA, Cindy Yu, MD, and Royce
More informationVisceral pleural invasion (VPI) of lung cancer has been
ORIGINAL ARTICLE Visceral Pleural Invasion Classification in Non Small- Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer: Validation Analysis Based on a
More informationStage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationSagar Damle, MD University of Colorado Denver May 23, 2011
Sagar Damle, MD University of Colorado Denver May 23, 2011 We have debated many times. Here are the topics, and a recap of the last few Pre-operative nutrition Babu pro; Damle con Utility of ECMO Babu
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationTitle: What has changed in the surgical treatment strategies of non-small cell lung cancer in
1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the
More informationPredictors of unexpected nodal upstaging in patients with ct1-3n0 non-small cell lung cancer (NSCLC) submitted to thoracoscopic lobectomy
Original Article on Thoracic Surgery Page 1 of 10 Predictors of unexpected nodal upstaging in patients with ct1-3n0 non-small cell lung cancer (NSCLC) submitted to thoracoscopic lobectomy Giuseppe Marulli*,
More information